Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy

International Journal of Clinical Oncology

Volumn 13, Issue 6, 2008, Pages 510-514

  Kanai, Kunimitsu ^a   Kikuchi, Eiji ^a   Ohigashi, Takashi ^a   Miyajima, Akira ^a   Nakagawa, Ken ^a   Nakashima, Jun ^a   Oya, Mototsugu ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Gemcitabine; Paclitaxel; Second line chemotherapy; Urothelial carcinoma

Indexed keywords

CIMETIDINE; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; GEMCITABINE; METHOTREXATE; PACLITAXEL; VINBLASTINE;

ADVANCED CANCER; ANEMIA; ARTICLE; BODY TEMPERATURE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONFIDENCE INTERVAL; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; KIDNEY DYSFUNCTION; LABORATORY TEST; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UROGENITAL TRACT TUMOR; UROTHELIAL CARCINOMA;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; DEOXYCYTIDINE; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 57849147736     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-008-0779-x     Document Type: Article

References (18)

1. C.N. Sternberg A. Yagoda H.I. Scher 1988 M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium J Urol 139 461 469
2. C.J. Logothetis F.H. Dexeus L. Finn 1990 A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors J Clin Oncol 8 1050 1055
3. S.B. Saxman K.J. Propert L.H. Einhorn 1997 Long-term follow-up of a phase III Intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a Cooperative Group study J Clin Oncol 15 2564 2569
4. I. Tannock M. Gospodarowicz J. Connolly 1989 M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience J Urol 142 289 292
5. J.P. Connor C.A. Olsson M.C. Benson 1989 Long-term follow-up in patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) for transitional cell carcinoma of urinary bladder: cause for concern Urology 34 353 356
6. V. Lorusso C.F. Pollera M. Antimi 1998 A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer Eur J Cancer 34 1208 1212
7. W.M. Stadler T. Kuzel B. Roth 1997 Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer J Clin Oncol 15 3394 3398
8. M.J. Moore I.F. Tannock D.S. Ernst 1997 Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer J Clin Oncol 15 3441 3445
9. B.J. Roth R. Dreicer L.H. Einhorn 1994 Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group J Clin Oncol 12 2264 2270
10. D. Papamichael C.J. Gallagher R.T. Oliver 1997 Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter Br J Cancer 75 606 607
11. M.L. Rothenberg A. Sharma G.R. Weiss 1998 Phase I trial of paclitaxel and gemcitabine administered every 2 weeks in patients with refractory solid tumors Ann Oncol 9 733 738
12. C.N. Sternberg F. Calabro G. Pizzocaro 2001 Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy Cancer 92 2993 2998
13. A.A. Meluch F.A. Greco H.A. Burris 2001 Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie Pearl Cancer Research Network J Clin Oncol 19 3018 3024
14. T. Takahashi S. Higashi H. Nishiyama 2006 Biweekly paclitaxel and gemcitabine for patients with advanced urothelial cancer ineligible for cisplatin-based regimen Jpn J Clin Oncol 36 104 108
15. D.S. Kaufman M.A. Carducci T.M. Kuzel 2004 A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer Urol Oncol 22 393 397
16. J. Li B. Juliar C. Yiannoutsos 2005 Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study J Clin Oncol 23 1185 1191
17. H. von der Maase S.W. Hansen J.T. Roberts 2000 Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study J Clin Oncol 18 3068 3077
18. J.D. Hainsworth A.A. Meluch S. Litchy 2005 Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium Cancer 103 2298 2303